H.C. Wainwright raised the firm’s price target on Avadel Pharmaceuticals to $27 from $25 and keeps a Buy rating on the shares post the Q1 report. The analyst believes investors are “missing the forest for the trees on QoQ LUMRYZ dynamics.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Is AVDL a Buy, Before Earnings?
- Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
- Avadel Pharmaceuticals call buyer realizes 17% same-day gains
- Avadel Pharmaceuticals Shifts to Nasdaq, Ends ADR Program
- Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
